Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY) study

Jacobo Mintzer, MD, Medical University of South Carolina, Charleston, SC, discusses the Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY) study (NCT05644262), which evaluated a combination of THC and CBD in the treatment of agitation in patients with Alzheimer's disease. Dr Mintzer highlights that the study demonstrated significant improvements in agitation symptoms, and the next plans are to expand these findings into a broader population. This interview took place at the 2026 Alzheimer's Association International Conference (AAIC) in London, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.